Exercise in Men with Metastatic Castrate-Resistant Prostate Cancer, the INTERVAL Study - Interview with Fred Saad

(Length of Conversation: 9 min)

Fred Saad and Charles Ryan discuss the Movember Foundation sponsored, INTense Exercise foR surVivAL Among Men With Metastatic Castrate-Resistant Prostate Cancer Study (INTERVAL).  This is a randomized phase 3 study of exercise in men with metastatic castrate-resistant prostate cancer (mCRPC). The objective of the study is to determine if high intensity aerobic and resistance training plus psychosocial support increases overall survival compared to psychosocial support alone in patients with mCRPC. They discuss eligibility criteria, lifestyle intervention at a phase 3 level, supervised, personalized exercise versus standard of care and the challenges associated with a trial of its kind. (NCT02730338)

Biographies:

Fred Saad MD, FRCS is Professor and Chief of Urology and Director of G-U Oncology at the University of Montreal Hospital Centers (CHUM). He holds the U of M Endowed Chair in Prostate Cancer Research and is Director of the molecular oncology research lab in Prostate Cancer. He is the past Chair of the National Cancer Institute of Canada G-U Group and the Canadian Urologic Oncology Group. Dr. Saad has been involved in most of the important clinical trials in advanced prostate cancer over the last 20 years and presently sits on 7 steering committees of international clinical trials. In 2014 he received the lifetime achievement award for research from the CHUM Research Center.

Charles Ryan, MD.